Clinical Trial · NCT03568799

4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

Overview

This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules. \[18F\]Fluoroglutamine PET may provide additional information that help diagnose lung cancer.

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase

N/A

Contacts

Hui Wang, MD (PRINCIPAL_INVESTIGATOR)

Hui Wang, MD (CONTACT)

wanghauishanghai@hotmail.com

86-02125078590

ClinicalTrials.gov

NCT03568799

Drug / Compound

Fluoroglutamine

Isotope(s):

Target(s):

Glutaminolytic Activity

Ligand Class: Small Molecules

Eligibility

Inclusion

Sexually active subjects agree to use condoms and/or their partners of reproductive potential to use a method of effective birth control during imaging period of 2 weeks;
Patients can finish PET/CT scan without tranquilizers;
The patient must be able to give informed consent;
Age between 18-79;
* Patients are given the opportunity to participate in the study if

Exclusion

Patients with active lung infection;
From assays obtained \<2 weeks prior to study enrollment（ULN：the upper limit of normal value ）:Bilirubin\>1.5\*ULN,AST/ALT \>2.5 \* ULN, Albumin\< 3 g/dl, GGT \> 2.5 x ULN if ALP\> 2.5 x ULN, Creatinine\>1.5\*ULN or creatinine clearance \<60ml/min；
Inability or refusal to have at least one peripheral intravenous line for intravenous access;
Pregnant or lactating patients;
* Patients with any of the following conditions will be excluded